ABSTRACT
Recent advances in the understanding of prostate cancer biology have led to the development of drugs directed against precise molecular alterations in the prostate tumor cell. Targeting specific pathways to stop cancer growth is generally less toxic to normal cells and improves tolerability, and thus anticancer drug discovery has shifted from an empiric random screening approach to a more rational and mechanistic, target-directed approach, where specific abnormalities in cell functioning are modulated in a classic drug-receptor fashion (1). Endothelins (ETs) and their receptor have emerged as a potential target in prostate cancer and will be discussed in detail in this chapter.
